Aggressive social media marketing by influencers has fuelled a surge in over-the-counter use of the diabetes and obesity ...

The Fed kept rates steady, as most economists had expected, but struck a more hawkish tone, causing a mid-afternoon stock sell-off.

Novo Nordisk A/S (NYSE:NVO) came up during the show in the context of trade discussions between the US and Europe and ...

U.S.-listed shares of Novo Nordisk (NVO) fell sharply for a second straight day Wednesday, this time after Bank of America ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Danish leader will face a challenging landscape among competitors ...

U.S. equities were mixed at midday with the market reacting to a strong report on the U.S. economy while awaiting the Federal ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...

Investors weren’t buying the dip en masse this time. Novo’s ADRs were down 3.5% to $52.04 in premarket trading Wednesday.

The idea is that SYH2086 can be paired with Rezdiffra, a selective thyroid hormone receptor agonist that became the first FDA-approved drug for metabolic dysfunction-associated steatohepatitis (MASH) ...

Novo Nordisk's technical chart is displaying a largely bearish trend amid a profit warning tied to its blockbuster obesity ...